![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1463649
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå : Áö¿ª ºÐ¼® - Á¦Ç°º°, ¼ö¼úº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2030³â)Asia Pacific Aortic Valve Replacement Devices Market Forecast to 2030 - Regional Analysis - by Product, Surgery, and End User . |
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº 2022³â 13¾ï 2,315¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 34¾ï 8,938¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 12.9%·Î ÃßÁ¤µË´Ï´Ù.
´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ Áøº¸°¡ ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀ» µÞ¹Þħ
°æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº Àúħ½À ¼ö¼ú ÀýÂ÷(MIS)ÀÇ °³¹ßÀº ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ(AS)ÀÇ Ä¡·á¸¦ Çö´ëÈÇÏ¿´½À´Ï´Ù. °æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀº Á¾·¡ÀÇ °³½É¼úº¸´Ù ħ½ÀÀÌ Àû±â ¶§¹®¿¡ Áö±Ý±îÁö ¼ö¼úÀÇ ´ë»óÀÌ µÇÁö ¾Ê¾Ò´ø °íÀ§ÇèÀÇ È¯ÀÚ¿¡¼µµ Ä¡·á¸¦ ¹Þ°Ô µÇ¾ú½À´Ï´Ù. °Ô´Ù°¡, Àç·á¿Í µðÀÚÀÎÀÇ °³¹ßÀº ´õ ưưÇÏ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀº ´ëµ¿¸ÆÆÇ¸· ġȯ¼úÀ» °³¹ßÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÇÕº´ÁõÀÇ À§ÇèÀ» °¨¼Ò½Ãŵ´Ï´Ù.
´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±âÀÇ ±â¾÷¿¡ ÀÇÇÑ ¸î °¡Áö ±â¼úÀû Áøº¸´Â ´ÙÀ½°ú °°½À´Ï´Ù.
2023³â 1¿ù, Abbot»ç´Â °³½É¼ú À§ÇèÀÌ ³ôÀº ½É°¢ÇÑ ´ëµ¿¸Æ ÆÇ¸· ÇùÂøÁõ ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇÑ °æ Ä«Å×ÅÍ ´ëµ¿¸Æ ÆÇ¸· À¯Ä¡(TAVI) ½Ã½ºÅÛ '³ªºñÅç'ÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. NavitolÀº AbbottÀÇ ±¤¹üÀ§ÇÑ °æ°æ Ä«Å×ÅÍ ±¸Á¶ ½ÉÀå Æ÷Æ®Æú¸®¿À¿¡ Âü°¡ÇÑ ÃֽŠÁ¦Ç°À¸·Î ÀÇ»ç¿Í ȯÀÚ¿¡°Ô ´Ù¾çÇÑ ½É°¢ÇÑ ½ÉÀå Áúȯ¿¡ ´ëÇÑ Ä§½ÀÀÌ ÀûÀº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.
2021³â 9¿ù, AbbotÀº ´ëµ¿¸Æ ÆÇ¸·°ú ½Â¸ðÆÇ Áúȯ ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» °³¼±Çϱâ À§ÇØ Epic Plus ¹× Epic Plus Supra Stented Tissue ValvesÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ »õ·Î¿î ÀåÄ¡·Î AbbotÀº ¿¡ÇÈ ¼ö¼ú¿ë ¹ëºê Ç÷§ÆûÀ» È®ÀåÇß½À´Ï´Ù.
2021³â 8¿ù, þ³ªÀÌ ÃÖÃÊÀÇ Àεµ 3D ÇÁ¸°ÆÃ ½ÉÀå ¹ëºê°¡ °³¹ßµÇ¾ú½À´Ï´Ù. »õ·Î¿î ½ÉÀå ¹ëºê´Â 3D ÇÁ¸°Å͸¦ »ç¿ëÇÏ¿© °³¹ßµÇ¾úÀ¸¸ç Àΰø ½ÉÀå ¹ëºê¿Í °ü·ÃµÈ ¹®Á¦¸¦ ±Øº¹ ÇÒ ¼öÀÖ¾ú½À´Ï´Ù. µû¶ó¼, ±â¼úÀÇ Áøº¸´Â ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå °³¿ä
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀº ¼¼°è ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ³ëÀÎ Àα¸ Áõ°¡, ½ÉÇ÷°ü Áúȯ Áõ°¡, Çõ½ÅÀûÀÎ Á¦Ç° °¡¿ë¼º µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀÇ ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº Á¦Ç°, ¼ö¼ú, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
Á¦Ç°º°·Î, ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ¹«ºÀÇÕ ¹ëºê¿Í ±â°è½Ä ¹ëºê·Î ±¸ºÐµË´Ï´Ù. 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ¹«ºÀÇÕ ¹ëºê°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¼ö¼úÀ» ¹ÙÅÁÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº ³·Àº ħ½À ¼ö¼ú°ú °³º¹ ¼ö¼ú·Î ³ª´¹´Ï´Ù. 2022³â¿¡´Â ³·Àº ħ½À ¼ö¼ú ºÎ¹®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå¿¡¼ ´õ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±â¹ÝÀ¸·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ¹× ±âŸ·Î ºÐÇҵ˴ϴÙ. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀå Á¡À¯À²¿¡¼ Ãִ븦 Â÷ÁöÇÕ´Ï´Ù.
±¹°¡º°·Î º¼ ¶§ ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ºÐ·ùµË´Ï´Ù. Áß±¹Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú ±â±â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
Abbott Laboratories, Artivion Inc, Boston Scientific Corp, Edwards Lifesciences Corp, LivaNova Plc, Medtronic Plc, Venus MedTech HangZhou Inc.
The Asia Pacific aortic valve replacement devices market is expected to grow from US$ 1,323.15 million in 2022 to US$ 3,489.38 million by 2030. It is estimated to grow at a CAGR of 12.9% from 2022 to 2030.
Advancements in Aortic Valve Replacement Devices Fuels Asia Pacific Aortic Valve Replacement Devices Market
The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.
A few technological advancements by the players in the aortic valve replacement devices are mentioned below:
In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.
In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
In August 2021, the first Made in India 3D printed heart valve was developed in Chennai. The new heart valves were developed using 3D printers, which could overcome the problems related to artificial heart valves. Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.
Asia Pacific Aortic Valve Replacement Devices Market Overview
The Asia Pacific aortic valve replacement devices market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The region holds a significant share of the global aortic valve replacement devices market. The market in Asia Pacific is expected to witness significant growth during the forecast period due to factors such as rising elderly population, growing cardiovascular diseases, and innovative product availability.
Asia Pacific Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Aortic Valve Replacement Devices Market Segmentation
The Asia Pacific aortic valve replacement devices market is segmented into product, surgery, end user, and country.
Based on product, the Asia Pacific aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger Asia Pacific aortic valve replacement devices market share in 2022.
Based on surgery, the Asia Pacific aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger Asia Pacific aortic valve replacement devices market share in 2022.
Based on end user, the Asia Pacific aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest Asia Pacific aortic valve replacement devices market share in 2022.
Based on country, the Asia Pacific aortic valve replacement devices market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific aortic valve replacement devices market in 2022.
Abbott Laboratories, Artivion Inc, Boston Scientific Corp, Edwards Lifesciences Corp, LivaNova Plc, Medtronic Plc, and Venus MedTech HangZhou Inc, are some of the leading companies operating in the Asia Pacific aortic valve replacement devices market.